Alan H. Shih

11.9k citations

37 papers · 3.8k indexed · 1 hit paper · h-index 25

Molecular Biology top 2%
Hematology top 1%
Genetics top 1%
Oncology top 5%
Cancer Research top 5%

Co-authors: Ross L. Levine Eric C. Holland Omar Abdel‐Wahab Jay P. Patel Sue Zhong Paolo Salomoni Ailan Guo Wei Gu
Topics: Acute Myeloid Leukemia Research (22 papers)Epigenetics and DNA Methylation (15 papers)Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers)
Cited by: Hematology Genetics Cancer Research
Journals: Nature The Journal of Experimental Medicine Nature reviews. Cancer
Partner nations: United States France Netherlands

In The Last Decade

Alan H. Shih

37 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The role of mutations in epigenetic regulators in myeloid malignancies

2012 518 citations Alan H. Shih, Omar Abdel‐Wahab et al. Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Alan H. Shih

Since Specialization

Citations

This map shows the geographic impact of Alan H. Shih's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan H. Shih with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan H. Shih more than expected).

Fields of papers citing papers by Alan H. Shih

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan H. Shih. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan H. Shih. The network helps show where Alan H. Shih may publish in the future.

Co-authorship network of co-authors of Alan H. Shih

This figure shows the co-authorship network connecting the top 25 collaborators of Alan H. Shih. A scholar is included among the top collaborators of Alan H. Shih based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan H. Shih. Alan H. Shih is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights 2024 ·JCO Precision Oncology ·Shivani Handa,(unknown),Michelle Becker,(unknown),(unknown),Jonathan Feld,Douglas Tremblay,Bridget K. Marcellino,(unknown),John Mascarenhas,Alan H. Shih	3
2	Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML 2020 ·Cancer Discovery ·Sheng Li,(unknown),Jiahui Wang,Cem Meydan,Jacob L. Glass,Alan H. Shih,Ruud Delwel,Ross L. Levine,Christopher E. Mason,Ari Melnick	24
3	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2 - and TET2 -Mutant Acute Myeloid Leukemia 2017 ·Cancer Discovery ·Alan H. Shih,Cem Meydan,Kaitlyn Shank,Francine E. Garrett-Bakelman,Patrick S. Ward,Andrew M. Intlekofer,Abbas Nazir,Eytan M. Stein,Kristina M. Knapp,Jacob L. Glass,Jeremy Travins,(unknown),Camelia Gliser,Christopher E. Mason,Katharine Yen,Craig B. Thompson,Ari Melnick,Ross L. Levine	71
4	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response 2017 ·Blood ·Michael Amatangelo,Lynn Quek,Alan H. Shih,Eytan M. Stein,Mikhail Roshal,Muriel D. David,Benoît Marteyn,Noushin Farnoud,Stéphane de Botton,Olivier Bernard,Bin Wu,Katharine Yen,Martin S. Tallman,Elli Papaemmanuil,Virginie Penard‐Lacronique,Anjan Thakurta,Paresh Vyas,Ross L. Levine	249
5	Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity 2017 ·Cancer Cell ·Hiroyoshi Kunimoto,Cem Meydan,Abbas Nazir,(unknown),Kaitlyn Shank,Franck Rapaport,(unknown),Elodie Pronier,Sara C. Meyer,Francine E. Garrett-Bakelman,Martin S. Tallman,Ari Melnick,Ross L. Levine,Alan H. Shih	62
6	A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations 2016 ·Molecular Cell ·Dali Han,Xingyu Lu,Alan H. Shih,Ji Nie,Qiancheng You,Meng Xu,Ari Melnick,Ross L. Levine,Chuan He	120
7	TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS 2013 ·The EMBO Journal ·Rachel Deplus,Benjamin Delatte,Marie K. Schwinn,Matthieu Defrance,Jacqui Méndez,Nancy E. Murphy,Mark A. Dawson,Michael Volkmar,Pascale Putmans,Emilie Calonne,Alan H. Shih,Ross L. Levine,Olivier Bernard,Thomas Mercher,Éric Solary,Marjeta Urh,Danette L. Daniels,François Fuks	387
8	Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia 2013 ·Haematologica ·Alan H. Shih,(unknown),(unknown),(unknown),Omar Abdel‐Wahab,(unknown),Stephen D. Nimer,Ross L. Levine,Virginia M. Klimek	97
9	The role of mutations in epigenetic regulators in myeloid malignanciesbreakdown → 2012 ·Nature reviews. Cancer ·Alan H. Shih,Omar Abdel‐Wahab,Jay P. Patel,Ross L. Levine	518
10	Regulation of Hematopoietic Stem and Progenitor Cell Mobilization by Cholesterol Efflux Pathways 2012 ·Cell stem cell ·Marit Westerterp,Samuel Gourion‐Arsiquaud,Andrew Murphy,Alan H. Shih,Serge Cremers,Ross L. Levine,Alan R. Tall,Laurent Yvan‐Charvet	211
11	Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2 2012 ·Nature ·Claudia A. Doege,Keiichi Inoue,Toru Yamashita,David B. Rhee,(unknown),Ryousuke Fujita,Paolo Guarnieri,Govind Bhagat,William B. Vanti,Alan H. Shih,Ross L. Levine,Sara Nik,Emily I. Chen,Asa Abeliovich	293
12	IDH1 Mutations Disrupt Blood, Brain, and Barriers 2012 ·Cancer Cell ·Alan H. Shih,Ross L. Levine	10
13	c-Myc and β-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice 2008 ·Oncogene ·Hiroyuki Momota,Alan H. Shih,Mark Edgar,Eric C. Holland	37
14	Notch Signaling Enhances Nestin Expression in Gliomas 2006 ·Neoplasia ·Alan H. Shih,Eric C. Holland	154
15	Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 2005 ·Clinical Cancer Research ·Andrew B. Lassman,Michael R. Rossi,(unknown),Lauren E. Abrey,Frank S. Lieberman,(unknown),Kathleen R. Lamborn,William Pao,Alan H. Shih,John G. Kuhn,Richard K. Wilson,Norma J. Nowak,John K. Cowell,Lisa M. DeAngelis,Patrick Y. Wen,Mark R. Gilbert,Susan M. Chang,WK Alfred Yung,Michael D. Prados,Eric C. Holland	201
16	The Characteristics of Astrocytomas and Oligodendrogliomas Are Caused by Two Distinct and Interchangeable Signaling Formats 2005 ·Neoplasia ·Chengkai Dai,(unknown),Alan H. Shih,Xiaoyi Hu,Gregory N. Fuller,Marc K. Rosenblum,Eric C. Holland	42
17	Platelet-derived growth factor (PDGF) and glial tumorigenesis 2005 ·Cancer Letters ·Alan H. Shih,Eric C. Holland	163
18	Developmental neurobiology and the origin of brain tumors 2004 ·Journal of Neuro-Oncology ·Alan H. Shih,Eric C. Holland	25
19	The hPLIC Proteins May Provide a Link between the Ubiquitination Machinery and the Proteasome 2000 ·Molecular Cell ·Maurits F. Kleijnen,Alan H. Shih,Pengbo Zhou,Sushant Kumar,Raymond E. Soccio,Nancy Kedersha,Grace Gill,Peter M. Howley	305
20	The function of PML in p53-dependent apoptosis 2000 ·Nature Cell Biology ·Ailan Guo,Paolo Salomoni,Jianyuan Luo,Alan H. Shih,Sue Zhong,Wei Gu,(unknown)	378

About Alan H. Shih

Alan H. Shih is a scholar working on Hematology, Genetics and Developmental Neuroscience, having authored 37 papers that have together received 3.8k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (22 papers), Epigenetics and DNA Methylation (15 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers). The work is most often cited by research in Hematology (995 citations), Genetics (800 citations) and Cancer Research (618 citations). Alan H. Shih has collaborated with scholars based in United States, France and Netherlands. Frequent co-authors include Ross L. Levine, Eric C. Holland, Omar Abdel‐Wahab, Jay P. Patel, Sue Zhong, Paolo Salomoni, Ailan Guo, Wei Gu, Jianyuan Luo and Grace Gill. Their work appears in journals such as Nature, The Journal of Experimental Medicine and Nature reviews. Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact